肥胖药物开发商Corxel Pharmaceuticals将通过与特殊目的收购公司Amanat Acquisition Corp的合并在美国上市，双方于周一宣布。
新型减重疗法的成功推动了一波生物科技公司的投资热潮，这些公司希望在由诺和诺德（Novo Nordisk）和礼来（Eli Lilly）主导的快速增长领域中占据一席之地。Corxel预计将从SPAC交易以及同步的公开市场私募股权融资中获得约3.77亿美元；机构投资者已承诺向其投入3亿美元。
Obesity drug developer Corxel Pharmaceuticals will go public in the US through a merger with special purpose acquisition company Amanat Acquisition Corp , the companies announced on Monday.
公司正在推进口服产品候选药物；领军候选药CX11正用于肥胖、2型糖尿病及相关心代谢疾病的研发，相关工作正推进其进入后期开发阶段。
该交易预计将在2027年上半年完成；合并后的公司可能在纳斯达克上市。
SPAC是一种空壳公司，通过首次公开募股筹集资金，并利用这些资金与私人公司合并或收购，使其在无需传统IPO的情况下上市。
Leerink Partners担任PIPE融资的主承销商，而Evercore ISI、Guggenheim Securities、Cantor及LifeSci Capital则担任配售代理。
The success of newer weight-loss therapies has spurred a wave of investments by biotechs looking to capture a slice of the fast-growing sector dominated by Novo Nordisk Corxel is expected to receive roughly $377 million from the SPAC deal and concurrent private investment in public equity; institutional investors have committed $300 million to it The company is advancing oral product candidates; lead candidate CX11 is being developed for obesity, type 2 diabetes and related cardiometabolic conditions, with work ongoing to advance it into late-stage development The deal is anticipated to close in the first half of 2027; the combined company will likely list on the Nasdaq A SPAC is a shell company that raises capital through an initial public offering and uses the funds to merge with or acquire a private company, taking it public without a traditional IPO Leerink Partners is serving as lead placement agent for PIPE financing, while Evercore ISI, Guggenheim Securities, Cantor and LifeSci Capital are acting as placement agents